ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/triple-negative
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / Triple negative
20
trial(s) found.
NCT06926868
Advanced
Phase 2 / Phase 3
Not yet recruiting
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic
Triple-negative
Breast Cancer (
TNBC
)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment (
CA244-0008
)
bispecific EGFR/ERBB3 antibody
Breast cancer
Triple-negative breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06449222
Advanced
Phase 2
Recruiting
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in
Triple-negative
Breast Cancer (
BNT327-02
)
bispecific PD-L1/VEGFA antibody
Breast cancer
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06257264
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors (
BG-68501-101
)
CDK2 inhibitor
Bladder cancer
Breast cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT06103864
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic
Triple-negative
Breast Cancer (TROPION-Breast05) (
D7630C00001
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
antimetabolite
platinum-based antineoplastic agent
taxane
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
Breast cancer
Endometrial cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Solid tumour
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
NCT05498597
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours (
AMT-151-01
)
anti-FR-alpha antibody-drug conjugate
Adenocarcinoma
Cancer
Carcinoma
Endometrial cancer
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian cancer
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pancreatic adenocarcinoma
Pleural mesothelioma
Solid tumour
Triple-negative breast cancer
Uterine serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05382299
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic
Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (
ASCENT-03
)
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NSW
2217 - Kogarah - St George Hospital
2060 - North Sydney - Mater Hospital (WITHDRAWN)
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
2640 - Albury - Border Medical Oncology Research Unit (WITHDRAWN)
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart (WITHDRAWN)
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04986852
Advanced
Phase 2
Recruiting
A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic
Triple-Negative
Breast Cancer (
KEYNOTE-C14
)
anti-PD-1 monoclonal antibody
anti-VEGFR2 monoclonal antibody
Triple-negative breast cancer
WA
6009 - Nedlands - Hollywood Private Hospital
NCT04947189
Advanced
Phase 1 / Phase 2
Recruiting
4CAST
: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer
CYP17A1 inhibitor
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04739670
Advanced
Phase 2
Recruiting
A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic
Triple Negative
Breast Cancer (
BELLA
)
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Triple-negative breast cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT05852691
Advanced
Phase 2
paused
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic
Triple-Negative
Breast Cancer (
CO44194
)
anti-PD-1 monoclonal antibody
bispecific PD-1/LAG3 antibody
taxane
Breast cancer
VIC
3021 - St Albans - Western Health - Sunshine Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (18)
Not yet recruiting (1)
paused (1)
Recruitment Country and State
VIC (14)
NSW (13)
QLD (10)
WA (7)
SA (7)
NZ (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (6)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (20)
Cancer Therapy Class
PD-1/PD-L1
45%
PD-1
35%
PD-L1
15%
Trop2
15%
EGFR
10%
FR-alpha
10%
VEGF
10%
CDK2
10%
CDK4
10%
ER
10%
oestrogen axis
10%
ERBB3
5%
VEGFA
5%
CDK4 selective
5%
Nectin-4
5%
ERBB2
5%
MET
5%
CD39
5%
CDK6
5%
IL-2
5%
VEGFR2
5%
CYP17A1
5%
androgen axis
5%
CCR8
5%
TP53
5%
TP53 Y220C
5%
LAG3
5%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
3168 - Clayton - Monash Medical Centre (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
2060 - North Sydney - Mater Hospital (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
6009 - Nedlands - One Clinical Research (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
NA
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2217 - Kogarah - St George Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Breast adenocarcinoma
Triple-negative breast cancer
Gastrointestinal cancer
Thoracic cancer
Gynaecological cancer
Ovarian cancer
Upper gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Pancreatic cancer
Pancreatobiliary cancer
Gastroesophageal cancer
Urogenital cancer
Endometrial cancer
Head and neck cancer
Oesophageal cancer
Cervical cancer
Colorectal cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Viral-related cancer
Bladder cancer
Gastric cancer
Head and neck squamous cell carcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Epithelial Ovarian Cancer
Kidney cancer
Carcinoma
Male genital cancers
Prostate cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Clear cell renal cell carcinoma
Mesothelioma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
HER2-negative breast cancer
HER2-positive breast cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Peritoneal cancer
Primary peritoneal serous carcinoma
Endometrial carcinoma
Non-squamous non-small-cell lung cancer
Pleural mesothelioma
Melanoma
Renal pelvis cancer
HER2-low breast cancer
Biliary tract cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Primary fallopian tube serous carcinoma
Adenocarcinoma
Endometrial adenocarcinoma
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian adenocarcinoma
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Uterine serous carcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Skin cancer
Squamous non-small-cell lung cancer
dMMR solid cancer
Colorectal adenocarcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Urothelial carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy